Technetium-99m-dimercaptosuccinic acid renal scintigraphy and single photon emission computed tomography/computed tomography in patients with sickle cell disease

Conclusion 99mTc-DMSA scintigraphy and SPECT/CT identify renal lesions possible related to renal infarcts or infections in most adult patients with SCD and no clinical evidence of renal insufficiency. Prominent renal columns and increased renal size tend to occur in most of these patients.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research

Related Links:

Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
This article represents the findings from the queries over the first three months ’ queries and brings further clarity to our initial findings.Methods This quality improvement (QI) project was reviewed and approved by the Orlando Health/UFHealth Cancer Center Joint Oncology Committee for 2018-19. We began recording results of all E-FORSCE queries occurring after the law ’s implementation of July 1, 2018 through September 30, 2018. We informed each patient that the PDMP query had become mandatory in Florida, and we discussed the results of each query with each patient. Each query examined the last 12 months of t...
Source: Pallimed: A Hospice and Palliative Medicine Blog - Category: Palliative Care Tags: kollas opioid pain quality improvement statte Source Type: blogs
Condition:   Sickle Cell Disease Interventions:   Device: FDNIRS-DCS;   Device: MRI Sponsors:   Boston Children’s Hospital;   National Heart, Lung, and Blood Institute (NHLBI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Novartis announced it won U.S. FDA approval for its experimental sickle cell disease drug, Adakveo.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
Crizanlizumab binds to P-selectin, a cell adhesion protein that plays a central role in the multicellular interactions that can lead to vaso-occlusion in sickle cell disease.FDA Approvals
Source: Medscape Pediatrics Headlines - Category: Pediatrics Tags: Hematology-Oncology News Alert Source Type: news
U.S. regulators have approved a new medicine that can help manage extremely painful sickle cell disease flare-ups
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Basel, November 15, 2019– Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo (crizanlizumab), previously known as SEG101, to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: CT Scan | Hematology | Nuclear Medicine | Sickle Cell Anemia | SPECT | Urology & Nephrology